Interestingly, recently, when we purified NG2-expressing cells from the CFPAC-1 cell line (NG2+/CFPAC-1) and subcutaneously injected them into NOD/SCID mice, we observed aggressive and rapid tumorigenesis compared to the injection of parental non-purified control cells (NG2−/CFPAC-1, unpublished work); this may highlight the potential of selectively targeting NG2/CSPG4-expressing cells, whether as PCs within the neovasculature or as CSCs for novel isoform-specific antibody- or vaccine-based therapeutic strategies, against solid organ cancers, such as HCC and PDAC. The gene discussed is CSPG4; the disease is hepatocellular carcinoma.